The life sciences company Janssen employs around 1,400 people in the canton of Schaffhausen - making it a major employer in the region. "We feel very much at home here," says Dr. Stephanie Striegler, General Manager of Janssen Schaffhausen. "One of the main strengths of the location is certainly the well-trained, highly qualified specialists," she adds. She is also positive about the short distances to members of the government and city council as well as official bodies. "We have a good working relationship with the economic development agency and have been supported by them in various projects," says Striegler.

Schaffhausen plays a decisive role 

The Johnson & Johnson company has been at home in Schaffhausen for over 80 years. As a market launch and growth location for the latest medicines, Janssen Schaffhausen plays an important role within the globally active group and is a strategic location for the aseptic production and packaging of so-called parenterals, i.e. pre-filled syringes and vials, as well as associated combination products. The importance of the Schaffhausen site within the life science parent company is high. "This is reflected in the fact that some of Johnson & Johnson's top pharmaceutical products are produced here," emphasizes Striegler.

"We have a good working relationship with the business development agency and have been supported by it in various projects."

Dr. Stephanie Striegler, General Manager, Janssen Schaffhausen

Production includes sterile filling, optical inspection, the assembly of autoinjectors - i.e. syringes that can be used to self-administer medication - and packaging. Schaffhausen also has a so-called "high containment plant" where chemical active ingredients are produced. Janssen Schaffhausen's portfolio also includes R&D activities such as analytical development and the manufacture of drugs for clinical trials. 

Investment in the Schaffhausen site

Since the 1990s, Johnson & Johnson has already invested over one billion US dollars in new technologies and facilities in Schaffhausen. And further expansion is already planned. "We are seeing a transformation of our pipeline towards an even greater patient focus and very specific needs. This requires investment in new technologies, more agile solutions, digitalization and automation," explains Striegler. This will enable the company to deliver vital medicines to patients around the world efficiently, robustly and reliably at all times. "We are also continuously investing in the right infrastructure - all with sustainable solutions in mind," says the General Manager. This further establishes the site as an important partner in the Janssen supply chain organization to provide patients worldwide with the latest medicines.